Xinhelix Biosciences Ranks Among Top 10 on the 2024 Qipu Seed List for Pharmaceutical Innovation with AI-Driven mRNA Neoantigen Cancer Vaccine

Nov 25, 2024 17:00 CST Updated 17:00

NeoCura

RNA Innovative Drug Developer

On November 24, the 2024 China Health Industry Innovation Summit and the 5th "Qipu Award" Ceremony was held in Shanghai. Experts, scholars, industry leaders, and innovators from the health industry gathered to explore innovative models and development prospects in the health sector.

The "2024 ChiPU Seed List" was released during the conference.NeoCura has been honored on the "2024 Pharmaceutical Innovation Qipu Seed List Top 10" for its outstanding innovation capabilities and achievements in the field of RNA-based therapeutics, standing out among numerous excellent companies.

The "CHIP AWARD" is known as the "Oscar Award" of the healthcare industry. This year's CHIP AWARD, themed "Creating Value, Crossing Cycles," aims to showcase and honor the "CHIP" in China's healthcare industry, lead the value innovation atmosphere in the healthcare sector, and promote the healthy development of the industry under the new healthcare reform environment. Among them, the CHIP Seed List is dedicated to continuously discovering innovative projects with genuine social significance and economic benefits, empowering future great enterprises that will lead industry innovation and development.

The Chip Award Review Panel consists of a hundred leaders and experts from the healthcare industry. It focuses on evaluating the clinical value, social value, and future potential of projects to select early-stage innovative projects with significant potential. The selection process lasts seven months and involves multiple rounds of expert reviews, including shortlisting, preliminary evaluation, re-evaluation, and final defense, ultimately determining the final list of awardees.NeoCura's participating project, "AI Technology-Based mRNA Tumor Neoantigen Vaccine Development," has demonstrated extraordinary potential and value in terms of technological innovation, industry prospects, team capabilities, and social benefits, ultimately earning a place on the honorary list.

In recent years, China has successively issued a number of policies to encourage the development and innovation of the biopharmaceutical industry. Against this backdrop, NeoCura has continuously increased its investment in R&D. The mRNA tumor neoantigen vaccine independently developed by NeoCura based on AI technology mainly involves sequencing the tumor cell tissues of subjects and analyzing them with AI algorithms to screen out high-quality neoantigen fragments from cellular mutations. The corresponding mRNA vaccine of the neoantigen sequence is synthesized in vitro and delivered into the subject's body to induce the body's natural immune response, thereby achieving the goal of suppressing and regressing tumor growth.

The vaccine has currently conducted clinical research (IIT) in several top-tier tertiary hospitals in China, including Peking Union Medical College Hospital, Peking University Cancer Hospital, and PLA General Hospital, obtaining positive safety and efficacy data. After the product is marketed, it will offer cancer patients a better treatment option.

In 2023, mRNA technology won the Nobel Prize in Physiology or Medicine, further unleashing its application potential. As a pioneer in China's mRNA field, NeoCura has consistently focused on cutting-edge global RNA technology platforms and innovative drug research, continuously seeking breakthroughs. The mRNA projects jointly submitted by the company have been successively...["14th Five-Year Plan" National Key R&D Program Key Special Project]And【Shenzhen Innovation and Entrepreneurship Plan - Major Science and Technology Special Project】Approved for project initiation, research strength and innovation capabilities have been recognized multiple times.

Creating Value, Spanning Cycles. Looking ahead, NeoCura will continue to address unmet clinical needs by accelerating original innovation, continuously enhancing core technological innovation capabilities, promoting the transformation of scientific research achievements and clinical applications, enabling more cancer patients to benefit from cutting-edge drug development results, and supporting the healthy growth of China's large health industry.

More content click "Read Original" below

Previous Recommendations

NeoCura Selected as One of the "Top 30 Supernova Enterprises," Shining with Innovation and Leading the Future of Health!

NeoCura Once Again Ranked on "Future Healthcare 100" List for the Third Time, Leading the New Future of RNA Innovative Drug Industry

Leading with Innovation, Adding Glory to Life | NeoCura Selected as One of "Fortune China's Most Socially Impactful Startups 2023"

NeoCura is a national high-tech enterprise that builds an RNA R&D platform and conducts innovative drug research based on AI technology. The company has established a multi-omics big data collection platform and a multi-layered biological omics database, utilizing AI and bioinformatics technologies for in-depth drug target discovery and fully automated drug design to upgrade its innovative RNA technology platform and advance drug research. It has set up leading R&D and production centers in Beijing, Shenzhen, and Guangzhou, China, supporting pipeline development, platform upgrades, and clinical needs.